Effect of new breakpoints proposed by clinical and laboratory standards institute in 2008 for evaluating penicillin resistance of Streptococcus pneumoniae in a Turkish University Hospital

Microbial Drug Resistance

Volumn 16, Issue 1, 2010, Pages 39-41

  Doǧan, Özlem ^a   Gülmez, Dolunay ^a   Hasçelik, Gülşen ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN DERIVATIVE;

ARTICLE; BACTERIAL MENINGITIS; BACTERIUM ISOLATE; CLINICAL LABORATORY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; REFERENCE VALUE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREND STUDY;

ACADEMIES AND INSTITUTES; ANTI-BACTERIAL AGENTS; HOSPITALS, UNIVERSITY; HUMANS; LABORATORIES, HOSPITAL; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PENICILLINS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; TURKEY;

STREPTOCOCCUS PNEUMONIAE;

EID: 77949600506     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2009.0084     Document Type: Article

References (18)

1. Chiou, C.C. 2006. Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance? Clin. Infect. Dis. 42:234-237.
2. [CLSI] Clinical and Laboratory Standards Institute. 2008. Development of in vitro Susceptibility Testing Criteria and Quality Control Parameters. Approved Guideline, 3rd edition. Document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
3. [CLSI] Clinical and Laboratory Standards Institute. 2008. Performance Standards for Antimicrobial Susceptibility Testing, 18th Informational Supplement M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
4. [CLSI] Clinical and Laboratory Standards Institute. 2007. Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Dias, R., D. Louro, and M. Canica. 2006. Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period. Antimicrob. Agents Chemother. 50:2098-2105.
6. Feldman, C. 2004. Clinical relevance of antimicrobial resistance in the management of pneumococcal communityacquired pneumonia. J. Lab. Clin. Med. 143:269-283.
7. Garau, J. 2002. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect. Dis. 2:404-415.
8. Gur, D., L. Mulazimoglu, and S. Unal. 2007. [In vitro susceptibility of respiratory isolates of Streptococcus pneumoniae and Streptococcus pyogenes to telithromycin and 11 other antimicrobial agents: Turkish results of e-BASKETT-II surveillance study]. Mikrobiyol. Bul. 41:1-9.
9. Mera, R.M., L.A. Miller, J.J. Daniels, J.G. Weil, and A.R. White. 2005. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn. Microbiol. Infect. Dis. 51:195-200.
10. Mera, R.M., L.A. Miller, and A. White. 2006. Antibacterial use and Streptococcus pneumoniae penicillin resistance: a temporal relationship model. Microb. Drug Resist. 12:158-163.
11. Metlay, J.P., J. Hofmann, M.S. Cetron, M.J. Fine, M.M. Farley, C. Whitney, and R.F. Breiman. 2000. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 30:520-528.
12. Montagnani, F., A. Fanetti, L. Stolzuoli, L. Croci, F. Arena, A. Zanchi, and C. Cellesi. 2008. Pneumococcal disease in a paediatric population in a hospital of central Italy: a clinical and microbiological case series from 1992 to 2006. J. Infect. 56:179-184.
13. Nowosiad, M., and S. Giedrys-Kalemba. 2008. Resistance, serotype and genetic diversity of Streptococcus pneumoniaeresistant strains isolated in the West Pomerania region of Poland in the years 2001-2005. Eur. J. Clin. Microbiol. Infect. Dis. 27:769-777.
14. Pallares, R., J. Linares, M. Vadillo, C. Cabellos, F. Manresa, P.F. Viladrich, R. Martin, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
15. Peterson, L.R. 2006. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin. Infect. Dis. 42:224-233.
16. Reingold, A., Gershman K., J. Hadler, M.M. Farley, L. Harrison, A. Glennen, R. Lynfeld, L. Lesher, J. Baumbach, G.L. Smith, A. Thomas, W.S. Schaffner, J. Jorgensen, B. Beall, C.G. Whitney, M. Moore, and M. Deutscher. 2008. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae-United States, 2006-2007. Morb. Mortal. Wkly. Rep. 57:1353-1355.
17. Sener, B., F. Tunckanat, S. Ulusoy, A. Tunger, G. Soyletir, L. Mulazimoglu, N. Gurler, L. Oksuz, I. Koksal, K. Aydin, A.N. Yalcin, D. Ogunc, A. Acar, and J. Sievers. 2007. A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004 2005. J. Antimicrob. Chemother. 60:587-593.
18. Yu, V.L., C.C. Chiou, C. Feldman, A. Ortqvist, J. Rello, A.J. Morris, L.M. Baddour, C.M. Luna, D.R. Snydman, M. Ip, W.C. Ko, M.B. Chedid, A. Andremont, and K.P. Klugman. 2003. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. 37:230-237.